MPNs

Olatoyosi Sobulo Odenike, MD, explored the risk factors for evolution to MPN AP/blast phase, outcomes for current treatment methods, and potential targeted therapies during a presentation.

The JAK1/JAK2 inhibitor Ruxolitinib has numerous clinical uses for the treatment of polycythemia vera, especially for adult patients who have had an inadequate response to hydroxyurea.

In the REVEAL study, having high-risk polycythemia vera was associated with lower survival at 4 years compared with low-risk disease.

Active phase 2 and 3 studies offer different concepts to the treatment myelofibrosis, according to Srdan Verstovsek, MD.

Adapting therapy to patients using the available criteria may be the key to future treatment in patients with polycythemia vera.

Haris Ali, MD, a hematology oncologist at the City of Hope Comprehensive Cancer Center, discusses common myeloproliferative neoplasms driver mutations. 

Above-average rates of polycythemia vera have been reported for over a decade due to causes unknown to experts. Intriguing new developments in the ongoing research of the genetic, toxicological, and environmental factors related to these cases have created reason to believe that this issue is not a thing of the past.

Haris Ali, MD, discussed the diagnosis and treatment of myelofibrosis with a group of physicians during a Targeted OncologyTCase-Based Roundtable event.

During a Targeted Oncology Case-Based Roundtable event, Andrew Kuykendall, MD, discussed the case of 68-year-old patients with myelofibrosis.

During a Targeted Oncology Case-Based Roundtable, Ruben Mesa, MD, discussed the prognostic risk systems in myelofibrosis.

Selinexor has been administered in combination with ruxolitinib to the first patient with treatment-naïve myelofibrosis as part of a phase 1/2 clinical trial.

Haris Ali, MD, discusses the use of ruxolitinib as peri-transplant treatment for patients with myelofibrosis.

The hepcidin mimetic rusfertide is suggested to reduce the need for phlebotomy in patients with polycythemia vera, according to the results of the phase 2 PTG-300-04 trial presented during the European Hematology Association 2021 Virtual Congress.

Jan Philipp Bewersdorf, MD, discusses the safety outcomes of a systematic review and meta-analysis of 43 studies investigating efficacy and safety of allogeneic hematopoietic cell transplant in 8739 patients with primary or secondary myelofibrosis.

A proportion of patients with myeloproliferative neoplasms were not prescribed medications needed for the management of comorbidities in the United Kingdom, a poster presented during the 2021 European Hematology Association Virtual Congress showed.

Subgroup analyses from the the phase 3 SIMPLIFY 1 and SIMPLIFY 2 trials show that achievement of transfusion independence by the 24th week of treatment is associated with an improvement in overall survival compared with continued transfusion dependence at that time point.

Based on a systematic review and meta-analysis , investigators say allogeneic hematopoietic cell transplant should be considered a standard of care option for patients with high-risk myelofibrosi.

The FDA has accepted and granted priority review to a new drug application for pacritinib for the treatment of patients with myelofibrosis and severe thrombocytopenia, defined as a platelet count less than 50x109/L.

After receiving a complete response letter by the FDA, an approval application for ropeginterferon alfa-2b for treatment for patients with polycythemia vera. has been resubmitted to the FDA.

In an interview with Targeted Oncology, Naseema Gangat, MD, MBBS, discussed her recommendations for managing pregnant patients with myeloproliferative neoplasms.

Haris Ali, MD, discusses research supporting the use of ruxolitinib for the treatment of myelofibrosis.

The most recent data on ruxolitinib support its continued use as frontline treatment of patients with myelofibrosis.

Srdan Verstovsek, MD, PhD, discusses the impacts of an analysis demonstrating longer survival in patients with myelofibrosis who received ruxolitinib versus those who didn’t.

A phase 3 study with the goal of demonstrating overall survival benefit with imetelstat versus best available therapy in patients with refractory myelofibrosis has dosed the first patient with the experimental agent.

The addition of parsaclisib to ruxolitinib led to improvement in spleen volume reduction and symptom burden in patients with myelofibrosis who had a suboptimal response on a standard dose of ruxolitinib alone, according to results from a phase 2 study.